Giving infliximab the best chance of working for Hidradenitis Suppurativa (HS) from the start means getting the dose right. In a retrospective study led by Dr. Christopher Sayed of University of North Carolina and published September 2019 in the Journal of the Academy of Dermatology, the authors investigated the variety of ways infliximab was used to treat people with HS.